Meeting
2022 ASCO Annual Meeting
Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial.
Authors
Alexander M. Menzies
Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia
Alexander M. Menzies , Robyn P.M. Saw , Serigne N. Lo , Maria Gonzalez , Sydney Ch'ng , Omgo E. Nieweg , Kerwin Frank Shannon , Peter M. Ferguson , Jenny HJ Lee , Helen Rizos , Robert V Rawson , Jonathan Stretch , John F. Thompson , Louise Emmett , Rony Kapoor , Andrew John Spillane , Richard A. Scolyer , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT01972347
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9580)
DOI
10.1200/JCO.2022.40.16_suppl.9580
Abstract #
9580
Poster Bd #
173
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.
First Author: Milton Jose De Barros E Silva
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas
Poster
2017 ASCO Annual Meeting
Preliminary results from the international neoadjuvant melanoma consortium (INMC).
First Author: Alexander M. Menzies
Poster
2016 ASCO Annual Meeting
Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.
First Author: Robyn Saw